PD-1

[Nature Communications] Researchers complemented PD-L1 immunohistochemistry and tumor mutation burden with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that could predict response to checkpoint blockade across tumor types.

[Nature Reviews Clinical Oncology] The authors discuss the current treatment landscape and detail their approach to first-line immunotherapy regimen selection for patients with advanced-stage, driver-negative NSCLC.

[Scientific Reports] The authors evaluated the relationship between GREB1L and lung adenocarcinoma using a wide range of databases and analysis tools, including TCGA, GEO, HPA, TIMER, cBioPortal, and MethSurv.

[Nature Communications] Using a transplantable mouse model of prostate carcinoma, scientists reported that tumor challenge leads to expansion of naïve neoantigen-specific CD8+ T cells and formation of a small population of non-recirculating tissue-resident memory T cells in several non-lymphoid tissues.

[Nature Biomedical Engineering] The authors showed in multiple murine tumor models that inulin-a widely consumed dietary fiber-formulated as a ‘colon-retentive’ orally administered gel could effectively modulate the gut microbiome in situ, induced systemic memory-T-cell responses and amplified the antitumour activity of the checkpoint inhibitor anti-programmed cell death protein-1.

[HUYABIO InternationalTM (PR Newswire, Inc.)] HUYABIO International™ announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency. The drug was approved based on data from a Phase IIb study that involved 23 patients with aggressive ATL in Japan.